This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

UCB Announces Data On Cimzia® (certolizumab Pegol) For Patients With Moderate To Severe Rheumatoid Arthritis At American College Of Rheumatology 2012 Congress

ATLANTA, Nov. 13, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology treatment and research, today announced findings from studies that evaluated the long-term outcomes, dosing, safety and impact on daily living of Cimzia ® (certolizumab pegol) for adults with moderate to severe rheumatoid arthritis (RA). The data were presented at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington, D.C., November 10-14, 2012.

"Because RA is a chronic disease that requires ongoing management, it is important to evaluate anti-TNF therapy in the long-term clinical setting. Studying this can help us to better understand long-term outcomes for patients who wish to maintain their health-related quality of life and ability to participate in daily activities," said Dr. Roy Fleischmann, Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center.

In the U.S., Cimzia ® is indicated for the treatment of adult patients with moderately-to-severely active RA. In the European Union, Cimzia ® in combination with methotrexate (MTX) is indicated for the treatment of moderate-to-severe active RA in adult patients inadequately responsive to disease-modifying anti-rheumatic drugs (DMARDs) including MTX. Cimzia ® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate.

An Analysis of Two Maintenance Dosing Regimens: The DOSEFLEX Trial

Presentation Title: Certolizumab Pegol Plus Methotrexate is Similarly Effective in Active Rheumatoid Arthritis Patients With or Without Secondary Non-Response to TNF Inhibitors: Post-hoc Analysis of a Phase IIIB Trial

    • Monday, November 12, 2012, from 9:00 AM - 6:00 PM
    • Location: Walter E. Washington Convention Center (WCC): Poster Hall (Hall B)

Results from the DOSEFLEX trial showed that in a population of adult patients with active moderate to severe RA, two dosing regimens of certolizumab pegol (200 mg every two weeks and 400 mg every four weeks*) plus methotrexate (MTX) showed comparable efficacy versus placebo and MTX in maintaining clinical response.

1 of 9

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs